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Aims To identify risk factors for left ventricular (LV) dysfunction in right ventricular (RV) pacing in the young.
Methods
and results
Left ventricular function was evaluated in 82 paediatric patients with either non-surgical (n ¼ 41) or surgical (n¼ 41)
complete atrioventricular block who have been 100% RV paced for a mean period of 7.4 years. Left ventricular short-
ening fraction (SF) decreased from a median (range) of 39 (24–62)% prior to implantation to 32 (8–49)% at last
follow-up (P , 0.05). Prevalence of a combination of LV dilatation (LV end-diastolic diameter .þ2z-values) and dys-
function (SF , 0.26) was found to increase from 1.3% prior to pacemaker implantation to 13.4% (11/82 patients) at
last follow-up (P ¼ 0.01). Ten of these 11 patients had progressive LV remodelling and 8 of 11 were symptomatic.
The only signiﬁcant risk factor for the development of LV dilatation and dysfunction was the presence of epicardial
RV free wall pacing (OR ¼ 14.3, P , 0.001). Other pre-implantation demographic, diagnostic, and haemodynamic
factors including block aetiology, pacing variables, and pacing duration did not show independent signiﬁcance.
Conclusion Right ventricular pacing leads to pathologic LV remodelling in a signiﬁcant proportion of paediatric patients. The major
independent risk factor is the presence of epicardial RV free wall pacing, which should be avoided whenever possible.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Right ventricular (RV) pacing is associated with asynchronous left
ventricular (LV) activation,
1 which can lead to deleterious pathologic
remodellingand LV failure.Severalrecent studieshave demonstrated
that high percentage of RV apical pacing correlates with morbidity
and mortality on heart failure in adults,
2–4 however, only limited
data are available in case of children. Karpawich et al.
5 described his-
tological changes (myoﬁbrillar hypertrophy, ﬁbrosis, fatty deposits)
anddepressedLVfunctioninpaediatricpatientswithcongenitalcom-
plete atrioventricular block (CAVB) and RV apical pacing. Two multi-
centre studies reported children with congenital CAVB who
developed severe dilated cardiomyopathy.
6,7 Interestingly, all of
those patients have been conventionally paced from a very young
age (median 1 and 7 days, respectively). No signs of acute inﬂam-
mation supporting the hypothesis of an immune-mediated process
were found in endomyocardial biopsies. Accidental reports and
small series could show positive and partially spectacular beneﬁts
from upgrades to biventricular pacing in RV pacing-induced heart
failure in children.
8–10 Finally, two larger multicentre surveys have
found a high percentage of pacing-associated cardiomyopathy
among congenital heart disease patients subjected to cardiac resyn-
chronization therapy (CRT).
11,12 Although it is doubtless that a dis-
tinct proportion of RV-paced paediatric patients may develop
clinicallysigniﬁcantLVdysfunction,theincidenceofthisphenomenon
is not known and the risk factors are poorly understood.
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Patients
A total of91 consecutive patients with CAVB,systemic left ventricles, and
biventricularcirculationwhounderwentpacemakerimplantationbetween
1984and2003 in a singletertiary paediatric cardiacsurgery centreserving
the whole population of the Czech Republic (10.7 millions of inhabitants)
have been retrospectively reviewed. Of these 91 patients, 82 have echo-
cardiographic data and were included in the present study. Forty-one
patients had non-surgical and 41 patients surgical CAVB. Demographic
data relating to block aetiology and pacing site are summarized in
Tables 1 and 2. Structural heart disease in the non-surgical CAVB group
consisted of patent arterial duct in all three cases closed interventionally
(n¼ 2) or surgically (n¼ 1). Of these three patients, one had positive,
one negative, and one unknown maternal antibody status, respectively.
Pacing
All patients had 100% RV pacing along with complete paced ventricular
activation.Table1summarizeslastpacingmodesandsites.Pacingleadpos-
itions were assigned according to implantation protocol data and con-
ﬁrmed by available chest X-rays. All RV apical and septal pacing sites
were endocardial, and all epicardial pacing leads were placed on the free
wall of the RV. Except for one case (change from VVIR to DDD pacing
20 days before last follow-up), all pacing mode and site changes were
performed .3 months before the last echocardiographic examination.
Thus only last follow-up pacing variables were used for further analysis.
Echocardiography
Echocardiographic data stored on analogue tapes during evaluations per-
formed prior to and immediately after the pacemaker implantation
(beforedischargefromhospital)andattheendoffollow-upwereanalysed.
Parasternal M-mode images were used to measure the LV end-diastolic
diameter (LVEDD) and end-systolic diameter (LVESD). Measurements
were taken at the point of peak diastolic LV free wall outward motion
and peak systolic inward motion, respectively, and LV shortening fraction
(SF) was calculated according to the following formula: (LVEDD2
LVESD)/LVEDD 100.Echocardiographicmeasurementswerecompared
with the normal values of body weight matched individuals,
13 using the
z-score method. Left ventricular dilatation and dysfunction were deﬁned
if both SF,26% and LVEDD.þ2z-values were present. Colour
Doppler echocardiography was performed for quantifying mitral
regurgitation using a four-grade scale. In ﬁve patients subjected to CRT
LV, end-diastolic and end-systolic volumes were prospectively measured
using the Simpson’s biplane method and ejection fraction was also
calculated.
Statistical analysis
Data are presented as mean (SD) or as median (range). The differences
between two groups were compared by unpaired t-test or Mann–
Whitney rank sum test as appropriate according to normality of distri-
bution.Two-sidedtestswereusedinallinstances.Forcategoricalvariables,
thex
2orFisher’sexacttestswereapplied.Multiplecomparisonsbetween
differentpatientgroupswereperformedbyone-wayanalysisofvarianceor
theKruskal–Wallisone-wayanalysisofvarianceonranksfollowedbypair-
wise comparisons using the Holm–Sidak or the Dunn’s method, respect-
ively.Repeatedmeasurementswithinthesamegroupofpatientswereana-
lysed by the Friedman repeated measures analysis of variance on ranks.
When overall signiﬁcance was found, pair-wise multiple comparisons
were performed by the Tukey test. Signiﬁcance level was accepted at
P , 0.05. Independent variables showing signiﬁcant univariate differences
related to the development of LV dilatation and dysfunction were
entered into a backward stepwise logistic regression analysis. Only pre-
implantationandpacing-relatedvariableswithapossiblecausativerelation-
shiptothestudiedendpointandwithoutpotentialdependenceonitwere
chosen. Theresult wasﬁnallyvalidatedbya bootstrapping methodusinga
BCaapproachforthecalculationofconﬁdenceintervalsatalevelofsigniﬁ-
cance a ¼ 0.05
14 and by the estimate of the shrinkage.
15 SigmaStat for
Windows Version 3.11 (Systat Software, Inc., San Jose, CA, USA), SPSS
Statistics 17.0 (SPSS, Inc., Chicago, IL, USA), and statistical software R
...............................................................................................................................................................................
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Table 1 Patient demographics
All patients Non-surgical
CAVB
Surgical
CAVB
P-value
a
Patients n 82 41 41 —
Age at ﬁrst implantation (years) Mean (SD) 7.0 (5.4) 8.2 (5.0) 5.8 (5.6) 0.045
Total duration of pacing (years) Mean (SD) 7.4 (4.5) 6.3 (3.6) 8.5 (5.1) 0.029
Duration of pacing from the last pacing site (years) Mean (SD) 6.6 (4.1) 6.1 (3.5) 7.1 (4.7) 0.256
Maternal antibody status
Positive n (%) 12 (29.3)
Negative n (%) 21 (51.2)
Unknown n (%) 8 (19.5)
Structural heart disease n (%) 44 (53.7) 3 (7.3) 41 (100.0) ,0.001
Cardiac surgery n (%) 42 (51.2) 1 (2.4) 41 (100.0) ,0.001
Pacing mode DDD/DDDR n (%) 48 (58.5) 21 (51.2) 27 (65.9) 0.262
Transvenous RV apical pacing n (%) 46 (56.1) 25 (61.0) 21 (51.2) 0.505
Transvenous RV septal pacing n (%) 17 (20.7) 10 (24.4) 7 (17.1) 0.587
Epicardial RV free wall pacing n (%) 19 (23.2) 6 (14.6) 13 (31.7) 0.102
CAVB, complete atrioventricular block; RV, right ventricle; SD, standard deviation.
aNon-surgical vs. surgical CAVB.
R.A. Gebauer et al. 10982.8.0(RFoundationforStatisticalComputing,Vienna,Austria,http://www.
r-project.org/foundation/) were used for statistical workup.
Results
Left ventricular size and function
There was a signiﬁcant decrease in LV SF and increase in the
LVEDD at the end of follow-up (Table 3). LV SF tends to
worsen more in the surgical vs. non-surgical CAVB group
between the post-implantation measurement and last follow-up
[mean 29 (11) vs. 24 (8)%, respectively, P ¼ 0.052]. Similar ten-
dency has, however, not been observed for the change in LVEDD.
The incidence of LV dilatation and dysfunction of patients with
available data was found to increase signiﬁcantly from 1.3% prior
to pacemaker implantation and 1.6% immediately after implan-
tation to 13.4% (11 of 82) patients at last follow-up (Table 3)
and differed depending on the pacing site (Figure 1). Although com-
plete echocardiographic data were not available for all follow-up
points, all patients with LV dilatation and dysfunction at last
follow-up had both pre- and early post-implantation echocardio-
graphic measurements included in the analysis. Detailed clinical
and echocardiographic data of the 11 patients with late LV
failure are shown in Table 4. All of these 11 patients had progress-
ive deterioration of LV SF as well as LV dilatation except Patient 2,
in whom LV size decreased (but did not normalize) after mitral
valve replacement for severe regurgitation. In six of 11 patients,
LVEDD increased by .2z-values and SF decreased by .10%
from early post-implantation evaluation to last follow-up. No sig-
niﬁcant haemodynamic or structural abnormalities other than the
inﬂuence of pacing explaining late LV dysfunctions were identiﬁed.
Myocardial biopsies were available in two of three patients with
non-surgical AV block who reached the deﬁned endpoint of LV
dilatation and dysfunction and did not reveal any signs of myocar-
ditis. The ﬁndings were, however, consistent with those reported
by Karpawich et al.
5 in patients with chronic RV pacing.
Univariate risk factors for late left
ventricular dilatation and dysfunction
Patients with late LV dysfunction were signiﬁcantly younger at
pacemaker implantation, had higher degree of baseline mitral
regurgitation, and had higher proportion of dual-chamber and epi-
cardial RV free wall pacing. The pre-implantation, early post-
implantation, and last follow-up parameter differences are listed
in Table 5.
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 2 Pacing site-speciﬁc patients’ data
RVA RVS RVFW P-value
(overall)
P-value (RVA
vs. RVS)
P-value (RVS
vs. RVFW)
P-value (RVA
vs. RVFW)
Patients n 46 17 19 —
Age at ﬁrst implantation
(years)
Median (range) 8.1 (0.1–24.3) 10.1 (0.4–18.8) 1.1 (0.0–7.2) ,0.001 NS ,0.05 ,0.05
Total duration of pacing
(years)
Mean (SD) 8.7 (4.2) 6.2 (5.0) 5.5 (3.9) 0.014 NS NS ,0.05
Duration of pacing from
the last pacing site
(years)
Mean (SD) 7.8 (4.2) 5.0 (3.5) 5.5 (3.9) 0.012 ,0.05 NS ,0.05
Structural heart disease n (%) 22 (47.8) 9 (52.9) 13 (68.4) 0.317
VSD n 31 3
AVSD n 31 4
ToF n 5— 1
d-TGA/DORV n 4— 2
AS subvalvular n 32—
Other n 32 3
Cardiac surgeryforSHD n (%) 22 (47.8) 7 (41.2) 13 (68.4) 0.207
Surgical AV block n (%) 21 (45.7) 7 (41.2) 13 (68.4) 0.178
Maternal antibody status
Positive n (%) 7 (15.2) 2 (11.8) 3 (15.8) 0.930
Negative n (%) 34 (73.9) 13 (76.5) 15 (78.9) 0.908
Unknown n (%) 5 (10.9) 2 (11.8) 1 (5.3) 0.732
Pacing mode DDD/
DDDR
n (%) 21 (45.7) 11 (64.7) 16 (84.2) 0.014 0.257 0.255 0.006
AS, aortic stenosis; AV, atrioventricular; AVSD, atrioventricular septal defect; DORV, double outlet right ventricle; d-TGA, d-transposition of great arteries; NS, non-signiﬁcant;
RVA, right ventricular apical pacing; RVFW, right ventricular free wall pacing; RVS, right ventricular septal pacing; ToF, tetralogy of Fallot; SD, standard deviation; VSD, ventricular
septal defect.
Risk factors for LV dysfunction in RV pacing 1099Multivariable risk factors for late left
ventricular dilatation and dysfunction
Four independent variables showing univariate signiﬁcance and lack
of cross-correlation (denoted by footnote in Table 5) were
entered into a backward stepwise logistic regression model that
identiﬁed the epicardial RV free wall pacing (OR ¼ 14.3, 95%
CI ¼ 2.3–78.2, P , 0.001) as the only signiﬁcant predictor of the
development of late LV dilatation and dysfunction (standard
error of the regression coefﬁcient b1 ¼ 3.85 and the estimate of
shrinkage ¼ 1.005).
Outcome of patients with late left
ventricular dilatation and dysfunction
Eight of the 11 patients were in NYHA Class II–IV. One of the 11
patients had to be placed on extracorporeal membrane oxygen-
ation for refractory heart failure and died (Patient 11, Table 4).
Another patient was successfully transplanted (Patient 3,
Table 4). Five patients were resynchronized (Patients 1, 4, 5, 7,
and 9, Table 4). Four of them by an upgrade to biventricular
pacing and the remaining one (Patient 1, Table 4) by programming
the pacemaker to low intervention rate to allow a narrow QRS
escape rhythm to prevail. These ﬁve patients showed major
reverse remodelling of the LV within 1–18 months of therapy
(Table 6). Two of these ﬁve patients (Patients 1 and 9) had
already been reported in the previous publication.
8 The remaining
four of 11 patients are compensated on heart failure medication
(Table 4).
Discussion
Our data have conﬁrmed the previously published reports on
the development of pathologic LV remodelling in a signiﬁcant
proportion of young patients with RV pacing. The incidence of
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Figure 1 Proportion of patients developing LV dilatation and
dysfunction (SF,26% and LVEDD .þ2z-values) according to
the pacing site. RVA, endocardial RV apical pacing; RVS, endocar-
dial RV septal pacing; RVFW, epicardial RV free wall pacing.
R.A. Gebauer et al. 1100........................ ...................... ......................
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Table 4 Patients with left ventricular dilatation and dysfunction at follow-up
No. Age
(years)
Diagnosis Surgical
procedure
Block AB P.
mode
P. site FUP
(yrs)
NYHA Outcome LVEDD z-score LV SF% MR grade
Pre Post Last Pre Post Last Pre Post Last
1
a 0.24 TAPVD Redirection Surg. DDD RVFW 0.66 III CRT
b 20.9 21.0 8.5 36 33 12 2 2 2
2 1.34 AVSD/I Patch Surg. DDD RVFW 13.21 I HFx 6.6 5.1 2.5 45 29 24 4 0 0
MV replacement
3
a 8.13 CCAVB — Cong. NA DDD RVA 4.13 III HTx 2.3 2.3 6.0 24 30 16 0.5 0 3
4 5.18 PA/IVS Biventricular repair Surg. DDD RVFW 4.79 II CRT 20.3 0.6 4.3 34 24 4 0 2 1
5
a 6.99 CoA, MVAN, VSD CoA repair Surg. DDD RVA 7.64 II CRT 1.8 0.1 3.5 32 44 19 3 0 0
VSD closure
MV replacement
6 1.41 AVSD/I Patch Surg. DDD RVFW 13.83 I HFx 20.5 2.0 3.6 38 24 20 0 0 0
MV replacement
7
a 0.44 VSD Patch Surg. DDD RVFW 2.16 II CRT 3.2 0.1 11.3 40 35 8 1 1 1.5
8 0.14 CCAVB — Cong. þ DDD RVFW 3.21 I HFx 2.6 3.7 4.5 35 15 20 0 0 0.5
9
a 0.00 CCAVB — Cong. þ DDD RVFW 3.36 IV CRT 4.0 0.1 10.2 30 26 10 2 0 3
10 6.86 IE TV replacement Surg. VVI RVFW 9.53 II HFx 1.2 0.5 4.6 41 31 24 1 0 0
11
a 1.13 ToF Repair Surg. DDD RVA 6.68 IV died 0.7 21.8 7.0 36 39 12 0 0 3
AB, speciﬁc maternal antibodies; Age, age at ﬁrst pacemaker implantation; AN, anomaly; AVSD/I, incomplete atrioventricular septal defect; CCAVB, congenital complete atrioventricular block; CoA, coarctation of aorta; cong., congenital; CRT,
cardiac resynchronization therapy; FUP, length of follow-up in years; HFx, heart failure medication; HTx, heart transplantation; IE, infectious endocarditis; last, last follow-up; LV, left ventricle; LVEDD, left ventricular end-diastolic diameter; MR,
mitral regurgitation; MV, mitral valve; NA, not available; P., pacing; PA/IVS, pulmonal atresia with intact ventricular septum; preimp, pre-implantation; postimp, post-implantation; RVA, endocardial right ventricular apex; RVFW, epicardial right
ventricular free wall; surg., surgical; ToF, tetralogy of Fallot; TV, tricuspid valve; VSD, ventricular septal defect.
aPatients, whose LVEDD increased by .2z-values and SF decreased by .10% from early post-implantation evaluation to last follow-up.
bResynchronization by spontaneous narrow QRS escape rhythm.
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Table 5 Univariate analysis of differences between patients with left ventricular dysfunction and dilatation at the last
follow-up and the rest of the group
Late LV dysfunction Yes (n 5 11) No (n 5 71) P-value
Pre-implantation parameters
Structural heart disease n (%) 8 (72.7) 36 (50.7) 0.208
Surgical AV block n (%) 8 (72.7) 33 (46.5) 0.121
Age at ﬁrst implantation (years) Mean (SD) 2.9 (3.2) 7.6 (5.4) 0.006
Age at ﬁrst implantation ,2 years
a n (%) 7 (63.6) 13 (18.3) 0.003
QRS duration (ms) Median (range) 80 (60–100) 80 (60–160) 0.857
LVEDD (z-score) Mean (SD) þ1.2 (2.4) þ1.9 (2.2) 0.403
LV SF (%) Mean (SD) 40 (8) 35 (6) 0.064
Mitral regurgitation  grade 2/4
a n (%) 4/11 (36.4) 4/70 (5.7) 0.010
NYHA class Median (range) 1 (1–2) 1 (1–2) 0.747
Early post-implantation parameters
Paced QRS duration (ms) Median (range) 130 (100–160) 135 (80–180) 0.665
LVEDD (z-score) Median (range) þ0.32 (21.80 to þ5.07) þ0.46 (24.02 to þ6.92) 0.617
LV SF (%) Mean (SD) 37 (8) 31 (8) 0.032
Mitral regurgitation  grade 2/4 n (%) 2/11 (18.2) 2/60 (3.3) 0.111
NYHA class Median (range) 1 (1–2) 1 (1–2) 0.775
Last follow-up parameters
Age at last follow-up Mean (SD) 9.2 (5.8) 15.2 (6.1) 0.003
Total duration of pacing (years) Median (range) 4.8 (0.7–13.8) 7.2 (0.1–20.1) 0.301
Duration of pacing from the last pacing site (years) Median (range) 4.1 (0.7–13.8) 6.1 (0.1–17.3) 0.327
DDD pacing
a n (%) 10/11 (90.9) 38/71 (53.5) 0.022
Transvenous RV apical pacing n (%) 3/11 (27.3) 43/71 (60.6) 0.052
Transvenous RV septal pacing n (%) 0/11 (0.0) 17/71 (23.9) 0.109
Epicardial RV free wall pacing
a n (%) 8/11 (72.7) 11/71 (15.5) ,0.001
Paced QRS duration (ms) Median (range) 160 (140–200) 155 (120–200) 0.014
LVEDD (z-score) Median (range) þ4.6 (þ2.5 to þ11.3) þ0.6 (23.4 to þ5.5) ,0.001
LV SF (%) Mean (SD) 17 (6) 33 (5) ,0.001
Mitral regurgitation  grade 2/4 n (%) 4/11 (36.4) 4/68 (5.9) 0.011
NYHA class Median (range) 2 (1–4) 1 (1–2) 0.009
AV, atrioventricular; DDD, dual-chamber pacing; LV, left ventricular; LVEDD, left ventricular end-diastolic diameter; NS, non-signiﬁcant; RV, right ventricular; SF, shortening
fraction.
aVariables entered into multivariable analysis.
..................... ..................... ..................... ..................... .....................
...............................................................................................................................................................................
Table 6 Patients who underwent CRT
No.
a Age at
CRT years
Follow-up on
CRT months
SPWMD (ms) IVMD (ms) SF% LVEDVi
(mL/sqm BSA)
EF%
Before After Before After Before After Before After Before After
1
b 0.90 1.0 250 210 50 10 12 38 119 83 32 76
4 11.59 7.5 337 2126 126 59 4 18 141 98 9 31
5 14.74 11.2 309 2111 45 11 19 31 144 67 48 68
7 2.62 13.0 270 240 50 15 8 33 249 58 22 70
9 3.40 17.5 230 222 40 22 10 27 163 67 28 62
Data immediately before CRT and after given follow-up on CRT are displayed. BSA, body surface area; CRT, cardiac resynchronization therapy; IVMD, interventricular mechanical
delay; SF, shortening fraction; SPWMD, septal to posterior wall motion delay; LVEDVi, left ventricular end-diastolic volume index.
aNumbers identify patients according to Table 3.
bResynchronization by spontaneous narrow QRS escape rhythm.
R.A. Gebauer et al. 1102LV dilatation and dysfunction (13.4%) is somewhat higher when
compared with data published recently (7.4 and 6.0%, respect-
ively).
10,16 This may be caused by different deﬁnitions used to
specify LV dysfunction and inﬂuenced by a bias introduced
through lack of information in nine of 91 originally eligible consecu-
tive patients, who could not be included in our analysis because
of insufﬁcient echocardiographic data but are likely not to have
developed clinically signiﬁcant heart failure because not coming
to clinical attention.
For the ﬁrst time, our data point to a pacing site-speciﬁc risk for
LV dysfunction development. The presence of epicardial RV free
wall pacing was the only signiﬁcant and independent multivariable
predictor of adverse outcome. One may speculate that epicardial
RV free wall pacing may carry more LV dyssynchrony than com-
monly used endocardial pacing sites. The quality of the retrospec-
tively analysed echocardiographic data was unfortunately not
sufﬁcient to prove this hypothesis by measuring mechanical LV dys-
synchrony indices and further studies speciﬁcally looking at this
issue are needed. The results of the analysis may point to additional
contributing factors for the development of pacing-induced LV car-
diomyopathy based on the presence of high sinus-driven pacing
rates associated with young age and a DDD pacing mode. When
combined, these risk factors may constitute a vicious circle of a
tachycardia–dyssynchrony-mediated cardiomyopathy.
6,8
Our ﬁndings also conﬁrm the beneﬁt of LV resynchronization in
symptomatic RV pacing-induced LV dysfunction in children as has
been reported previously.
8,10 Upgrading to biventricular pacing
or just switching the pacemaker off to allow an escape narrow
QRS rhythm to prevail may lead to successful reverse LV remodel-
ling. The importance of conventional pacing-induced systemic
ventricular dysfunction has been recently reported by two pub-
lished retrospective multicentre studies on CRT in paediatric and
congenital heart disease. Pacing-induced ventricular failure was a
major indication for CRT ranging from 44.7%
11 to 77.1%.
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Thepresentreporthasseverallimitations.First,theretrospective
study design did not allow for evaluation of complete echocardio-
graphic data sets. This may have inﬂuenced the results of univariate
and multivariate analyses. However, serial echocardiographic data
were available in all patients reaching the composite endpoint of
LV dilatation and dysfunction, thus excluding at least the possibility
that already existing pre-implantation dysfunction could have been
missed and interpreted as a consequence of pacing during later
follow-up. Secondly, measurement of LV SF may not be the best
method to reﬂect the degree of systolic LV dysfunction in the pre-
sence of dyssynchrony. However, a decrease in SF along with pro-
gressive LV dilatation is, in our opinion, a relatively solid marker of
pathologic LV remodelling, and changes in SF were well correlated
with changes in LV ejection fraction as measured by the biplane
Simpson’s method in patients undergoing CRT. Thirdly, LV dysfunc-
tion may have been potentially caused by operation in the surgical
AV block patients. However, development of LV dilatation and dys-
function has not been signiﬁcantly different between the non-
surgical and surgical AV block groups and aetiology of AV block
has not been identiﬁed as a signiﬁcant risk factor in the statistical
analysis. Furthermore, in the published reports
8,10 as well as in all
our patients, LV function was found to improve regardless of AV
block aetiology after CRT.
Clinical implications
The results of this study once again stress the need for prosyn-
chronization strategies in conventional cardiac pacing in the
young. Several reports have evaluated optimal pacing lead positions
in both adults and children. Karpawich et al. have been the ﬁrst to
show preserved LV function and myocardial ultrastructure during
pacing from RV septum (proximal His–Purkinje conduction
system) when compared with RV apex pacing.
17–19 Tse et al.
have mapped the RV septum to select a pacing site with the short-
est QRS duration. After 18 months of pacing, LV ejection fraction
in those patients was signiﬁcantly higher than in a control group
paced from the RV apex.
20 Finally, epicardial LV apical pacing has
been shown to carry minimal LV dyssynchrony and the lowest
decrease in maximum LV þdP/dt in both an acute animal and
human studies
21,22 and may be a promising substitute to RV epicar-
dial pacing in the young. Thus, there are alternative pacing
strategies available that should be studied prospectively in order
to better deﬁne optimal ventricular lead placement in the paedia-
tric age group. In the presence of a systemic LV, epicardial RV free
wall pacing should, however, be avoided whenever possible.
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